ZV 0203
Alternative Names: ZV-0203Latest Information Update: 06 Jan 2025
At a glance
- Originator Hangzhou Adcoris Biopharmacy; Zova Biotherapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Cell cycle inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 13 Sep 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (NCT05423977)
- 13 Sep 2024 Efficacy data from a phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Pharmacodynamics and adverse events data from the preclinical trials in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)